

## AGENDA

*Uniform Formulary Beneficiary Advisory Panel  
14 Jan 2010 @ 9:00 AM*

*Naval Heritage Center Theater  
701 Pennsylvania Ave. NW., Washington DC 20004*

- **Administrative Meeting (BAP members only @ 8:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

*Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.*

*The Committee made recommendations of the following drug classes during the Nov 2009 meeting:*

- *Drug Class Review: Phosphodiesterase Type 5 Inhibitors (PDE-5 inhibitors) for Pulmonary Arterial Hypertension*
- *Designated Newly Approved Drugs*
  - *Multiple Sclerosis-Disease Modulating Agents (MS-DMDs)- Extavia (interferon beta-1b injection)*
  - *Antidepressant -I Agents (AD-Is)- Aplenzin (bupropion hydrobromide extended release tablets)*
  - *Antidepressant -I Agents (AD-Is)- Savella (milnacipran tablets)*
  - *Overactive Bladder Drugs (OABs)- Gelnique (oxybutynin topical gel)*
  - *Narcotic Analgesics – Nucynta (tapentadol tablets)*
  - *Narcotic Analgesics - Ryzolt (tramadol extended release tablets)*
  - *Renin Angiotensin Antihypertensive Agents (RAAs) – Exforge HCT (valsartan/amlodipine/hydrochlorothiazide tablets)*
- *Status of Wellbutrin XL (bupropion hydrochloride extended release tablets ) on the Uniform Formulary*
- **Formulary status of drugs not in compliance with 2008 NDAA Section 703**

➤ **Panel Discussions**

*The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.*

➤ **Item for Information**

*Members of the DoD Pharmacoeconomic Center will present an informational discussion of the following:*

- *FY 09 Uniform Formulary Performance*